Founded in 2017, Urovant Sciences is a biopharmaceutical company committed to advancing innovative therapies for urological care. Urovant Sciences is committed to developing medicines for urological conditions that allow people to live healthier and happier lives. Their approach is rooted in social responsibility. They are committed to the health and well-being of the patients and healthcare providers they serve, to their employees, and to the communities in which they operate. Urovant Sciences supports policies that improve public health and access to life-impacting therapies regardless of race, ethnicity, or ability to pay.
At Urovant Sciences, they are Powered by People and Possibilities™. Every employee contributes to driving us forward. They each bring passion, purpose, and care to their work and they are bold in their approach to improve outcomes for patients and healthcare providers. They succeed through grit, determination, flexibility, and hard work and offer an encouraging and rewarding community where careers can flourish.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients living with urological conditions. Their current area of research focus is the Overactive Bladder (OAB). They are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third-line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
Their approach is defined by their passion for science and medicine, combined with their mission to advance urological care. They are committed to delivering meaningful products with significant benefits to their patients, their caregivers, and their treating healthcare providers. They maintain a quality and compliance-focused culture that enables and ensures employees follow all applicable regulatory requirements to safeguard our patients and the quality of their products.
Their Product Pipeline:
- Vibegron: Vibegron is a small molecule, β3 adrenergic agonist designed to selectively activate β3 receptors to relax the bladder muscle and improve urine storage. Vibegron is currently being studied for the treatment of OAB in men with benign prostatic hyperplasia (BPH).
- URO-902: Urovant Sciences’ second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. URO-902 has been evaluated in two Phase 1 studies in OAB patients and Urovant Sciences initiated a Phase 2 URO-902 study in 2019.
They aim to advance urologic patient care through bold innovation, based on diversity of thought, openness to new ideas, adaptation to change, integrity, and compassion. They develop innovative therapies and participate in exceptional licensing opportunities. Their goal is to be the leading specialty company: recognized and trusted by patients and providers for their commitment to urology. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood, or not adequately treated.